PRKCD and cancer: Conversely, kinases that regulate inflammation and immune responses, including PKCA, PKCD, PKCH, PKCT, IRAK4, RIPK1, RIPK2, RIPK3, and TBK157-59, were downregulated in at least three cancer types within IGF2BP-H group, with the exception of ccRCC, in which immune pathways were activated, consistent with our pathway enrichment results (Fig. 3A).